The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that
play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis …

The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia
(AML) has resulted in a different paradigm for treatment compared with most other cancers …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

Venetoclax, a selective B cell leukemia/lymphoma-2 (BCL2) inhibitor, has recently shown
activity in relapsed or refractory (R/R) acute myeloid leukemia (AML). Effective biomarkers …

Abstract CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for
treatment of hematological cancers. This study of extended CC‐486 dosing included …

The prognosis of relapsed acute myeloid leukaemia (AML) is poor and treatment is
challenging. While the most potent treatment modality for patients who achieve a complete …

Introduction: Acute myeloid leukemia [AML] is a heterogenous group of primary
hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed …

Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with
poor long-term outcomes with available therapies. Used as single agents, hypomethylating …

Azacitidine is recommended front-line treatment for older patients with acute myeloid
leukemia (AML) who are not candidates for intensive treatment regimens, and was recently …